

JC07 Rec'd PCT/PTO 19 FEB 2002

FORM PTO-1390 (REV. 9-2001)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER P/3610-26	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.5) 10/049980	
INTERNATIONAL APPLICATION NO. PCT/EP00/08268		INTERNATIONAL FILING DATE 11 August 2000		PRIORITY DATE CLAIMED 18 August 1999	
TITLE OF INVENTION FUNGICIDES					
APPLICANT(S) FOR DO/EO/US Tracey COOKE et al.					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input checked="" type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input checked="" type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). 9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). - unsigned 10. <input checked="" type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). including new pages 1-46 and Claims 1+3.					
Items 11 to 20 below concern document(s) or information included:					
11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with 37 CFR 1.82. 18. <input type="checkbox"/> A second copy of the published international application and English language translation. 19. <input type="checkbox"/> A second copy of the English language translation of the international application. 20. <input checked="" type="checkbox"/> Other items or information: PEFS print form. Postcard.					

EXPRESS MAIL CERTIFICATE

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Post Office Addressee (Mail Label EL 924374109 US) in an envelope addressed to: U.S. Patent and Trademark Office, PO Box 2327, Arlington, VA 22202, on Feb. 19.02


Dorothy Jenkins

Name of Person Mailing correspondence

Dorothy Jenkins
Signature

February 19, 2002

Date of Signature

U.S. APPLICATION NO. (if known, see 37 CFR 1.53) 10/049980		INTERNATIONAL APPLICATION NO. PCT/EP00/08268		ATTORNEY'S DOCKET NUMBER P/3610-26	
21. <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =				CALCULATIONS PTO USE ONLY	
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	
Total claims	3 - 20 =	0	x \$18.00	\$	
Independent claims	1 - 3 =	0	x \$84.00	\$	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00	\$	
TOTAL OF ABOVE CALCULATIONS =				\$	890.00
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				+	
SUBTOTAL =				\$	890.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$	
TOTAL NATIONAL FEE =				\$	890.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$	
TOTAL FEES ENCLOSED =				\$	890.00
				Amount to be refunded:	\$
				charged:	\$
a. <input checked="" type="checkbox"/> A check in the amount of \$ <u>890.</u> to cover the above fees is enclosed. Check No. 8465 b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>15-0700</u> . A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP 1180 Avenue of the Americas New York, NY 10036-8403 Tel: (212) 382 0700					
				 SIGNATURE Robert C. Faber NAME 24,322 REGISTRATION NUMBER	


Fungicides

5 This invention relates to compounds having fungicidal activity.

As a prior art including compounds similar to the compound according to the invention in the chemical structure, there have hitherto been known the specification of EP0288976. It discloses that the compounds protect plants against attack by harmful microorganisms, for
10 example phytopathogenic fungi, bacteria and viruses. Nevertheless, nothing is written about an eventual action of this sort of compounds on the metabolism phytopatogen organisms.

In a first aspect the invention provides the use of a compound of general formula I or salts thereof as phytopathogenic fungicides

15



where

A¹ is 3-Cl-5-CF₃-2-pyridyl;

A² is optionally substituted heterocyclyl or optionally substituted carbocyclyl (A² is

20 preferably phenyl, cyclohexyl, cyclopropyl or heterocyclyl, each of which may be substituted); excepted when L is -N(R₃)N(R₄)C(=O)- or -CH₂OCH₂-, then A₂ can not contain any heterocyclyl containing N or O;

L is a 3-atom linker selected from the list: -CH(R¹)N(R³)CH(R²)-, -N(R³)N(R⁴)C(=X)-, -C(=X)N(R³)CH(R¹)-, -CH(R¹)OC(=X)-, -CH(R¹)OCH(R²)-, -N(R³)C(=X)N(R⁴)-, -C(R¹)=C(R²)C(=X)-, -CH(R¹)N=C(R²)-, -O-N=C(R¹)-, -O-N(R³)C(=X)-, -N(R³)N(R⁴)CH(R¹), -N(R³)C(Y)=N-, -N=C(Y)-N(R³)-, -C(=X)-N(R³)N(R⁴)-, -C(Y)=N-N(R⁴)- and -N(R³)CH(R¹)C(=X)-; wherein A¹ is attached to the left hand side of linker L (L is preferably selected from the list: -CH(R¹)N(R³)CH(R²)-, -N(R³)N(R⁴)C(=X)-, -C(=X)N(R³)CH(R¹)-, -CH(R¹)OC(=X)-, -CH(R¹)OCH(R²)-, -N(R³)C(=X)N(R⁴)-, -C(R¹)=C(R²)C(=X)-, -CH(R¹)N=C(R²)-, -O-N=C(R¹)-, -O-N(R³)C(=X)-);

30

where R^1 and R^2 , which may be the same or different, are R^b , cyano, nitro, halogen, $-OR^b$, $-SR^b$ or optionally substituted amino (R^1 and R^2 are preferably hydrogen, acyl, optionally substituted alkyl, cyano or optionally substituted phenyl); R^3 and R^4 , which may be the same or different, are R^b , cyano or nitro (R^3 and R^4 are preferably hydrogen, acyl or optionally substituted alkyl); or any R^1 , R^2 , R^3 or R^4 group, together with the interconnecting atoms, can form a 5- or 6-membered ring with any other R^1 , R^2 , R^3 or R^4 , or any R^1 , R^2 , R^3 or R^4 group, together with the interconnecting atoms can form a 5- or 6-membered ring with A^2 ;

X is oxygen, sulfur, $N-OR^b$, $N-R^b$ or $N-N(R^b)_2$ (X is preferably oxygen or sulfur); and Y is halogen, $-OR^b$, $-SR^b$, $-N(R^b)_2$, $-NR^b(OR^b)$ or $-NR^bN(R^b)_2$;

wherein R^b is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; or hydrogen or acyl, or two adjacent R^b groups together with the nitrogen atom to which they are attached may form a 5- or 6-membered ring.

Preferred substituents on the 2-pyridyl group (A^1) are halogen, hydroxy, cyano, nitro, SF_5 , trialkylsilyl, optionally substituted amino, acyl, or a group $-R^a$, $-OR^a$ or $-SR^a$, or a group $-C(R^a)=N-Q$, where Q is $-R^a$, $-OR^a$, $-SR^a$ or optionally substituted amino, wherein R^a is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; or two adjacent substituents together with the atoms to which they are attached form an optionally substituted ring which can contain up to 3 hetero atoms. Especially preferred substituents are alkoxy, alkyl, cyano, halogen, nitro, alkoxycarbonyl, alkylsulfinyl, alkylsulfonyl and trifluoromethyl, particularly chlorine and trifluoromethyl.

Preferably, the 2-pyridyl group is substituted at the 3 and/or 5 position.

The invention also includes any of the compounds specifically exemplified hereinafter.

Any alkyl group may be straight or branched and is preferably of 1 to 10 carbon atoms, especially 1 to 7 and particularly 1 to 5 carbon atoms.

Any alkenyl or alkynyl group may be straight or branched and is preferably of 2 to 7 carbon atoms and may contain up to 3 double or triple bonds which may be conjugated, for example vinyl, allyl, butadienyl or propargyl.

- 5 Any carbocyclyl group may be saturated, unsaturated or aromatic, and contain 3 to 8 ring-atoms. Preferred saturated carbocyclyl groups are cyclopropyl, cyclopentyl or cyclohexyl. Preferred unsaturated carbocyclyl groups contain up to 3 double bonds. A preferred aromatic carbocyclyl group is phenyl. The term carbocyclic should be similarly construed. In addition, the term carbocyclyl includes any fused combination of carbocyclyl groups, for
10 example naphthyl, phenanthryl, indanyl and indenyl.

- Any heterocyclyl group may be saturated, unsaturated or aromatic, and contain 5 to 7 ring-atoms up to 4 of which may be hetero-atoms such as nitrogen, oxygen and sulfur. Examples of heterocyclyl groups are furyl, thienyl, pyrrolyl, pyrrolinyl, pyrrolidinyl, imidazolyl,
15 dioxolanyl, oxazolyl, thiazolyl, imidazolyl, imidazoliny, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, pyranyl, pyridyl, piperidiny, dioxanyl, morpholino, dithianyl, thiomorpholino, pyridaziny, pyrimidinyl, pyrazinyl, piperazinyl, sulfolanyl, tetrazolyl, triazinyl, azepinyl, oxazepinyl, thiazepinyl, diazepinyl and thiazolinyl. In addition, the term heterocyclyl includes fused
20 heterocyclyl groups, for example benzimidazolyl, benzoxazolyl, imidazopyridinyl, benzoxazinyl, benzothiazinyl, oxazolopyridinyl, benzofuranyl, quinolinyl, quinazolinyl, quinoxaliny, dihydroquinazolinyl, benzothiazolyl, phthalimido, benzofuranyl, benzodiazepinyl, indolyl and isoindolyl. The term heterocyclic should be similarly construed.

- 25 Any alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl group, when substituted, may be substituted by one or more substituents, which may be the same or different, and may be selected from the list: hydroxy; mercapto; azido; nitro; halogen; cyano; acyl; optionally substituted amino; optionally substituted carbocyclyl; optionally substituted heterocyclyl;
30 cyanato; thiocyanato; $-SF_5$; $-OR^a$; $-SR^a$ and $-Si(R^a)_3$, where R^a is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted. In the case of any carbocyclyl or heterocyclyl group the list includes additionally: alkyl, alkenyl and alkynyl, each of which may be substituted. Preferred substituents on any alkyl, alkenyl or alkynyl group are alkoxy, haloalkoxy or alkylthio, each containing 1 to 5 carbon atoms; halogen; or

optionally substituted phenyl. Preferred substituents on any carbocyclyl or heterocyclyl group are alkyl, haloalkyl, alkoxy, haloalkoxy or alkylthio, each containing 1 to 5 carbon atoms; halogen; or optionally substituted phenyl.

- 5 In the case of any alkyl group or any unsaturated ring-carbon in any carbocyclyl or heterocyclyl group the list includes a divalent group such as oxo or imino, which may be substituted by optionally substituted amino, R^a or $-OR^a$. Preferred groups are oxo, imino, alkylimino, oximino, alkyloximino or hydrazono.
- 10 Any amino group, when substituted and where appropriate, may be substituted by one or two substituents which may be the same or different, selected from the list: optionally substituted alkyl, optionally substituted amino, $-OR^a$ and acyl groups. Alternatively two substituents together with the nitrogen to which they are attached may form a heterocyclyl group, preferably a 5 to 7-membered heterocyclyl group, which may be substituted and may
- 15 contain other hetero atoms, for example morpholino, thiomorpholino or piperidinyl.

The term acyl includes the residues of sulfur and phosphorus-containing acids as well as carboxylic acids. Typically the residues are covered by the general formulae $-C(=X^a)R^c$, $-S(O)_pR^c$ and $-P(=X^a)(OR^a)(OR^a)$, where appropriate X^a is O or S, R^c is as defined for R^a , $-OR^a$, $-SR^a$, optionally substituted amino or acyl; and p is 1 or 2. Preferred groups are –

20 $C(=O)R^d$, $-C(=S)R^d$, and $-S(O)_pR^d$ where R^d is alkyl, C_1 to C_5 alkoxy, C_1 to C_5 alkylthio, phenyl, heterocyclyl or amino, each of which may be substituted.

Complexes of compounds of the invention are usually formed from a salt of formula MAN_2 ,

25 in which M is a divalent metal cation, e.g. copper, manganese, cobalt, nickel, iron or zinc and An is an anion, e.g. chloride, nitrate or sulfate.

In cases where the compounds of the invention exist as the E and Z isomers, the invention includes individual isomers as well as mixtures thereof.

30

In cases where compounds of the invention exist as tautomeric isomers, the invention includes individual tautomers as well as mixtures thereof.

In cases where the compounds of the invention exist as optical isomers, the invention includes individual isomers as well as mixtures thereof.

The compounds of the invention have activity as fungicides, especially against fungal diseases of plants, e.g. mildews and particularly cereal powdery mildew (*Erysiphe graminis*) and vine downy mildew (*Plasmopara viticola*), rice blast (*Pyricularia oryzae*), cereal eyespot (*Pseudocercospora herpotrichoides*), rice sheath blight (*Pellicularia sasakii*), grey mould (*Botrytis cinerea*), damping off (*Rhizoctonia solani*), wheat brown rust (*Puccinia recondita*), late tomato or potato blight (*Phytophthora infestans*), apple scab (*Venturia inaequalis*), and glume blotch (*Leptosphaeria nodorum*). Other fungi against which the compounds may be active include other powdery mildews, other rusts, and other general pathogens of Deuteromycete, Ascomycete, Phycomycete and Basidiomycete origin.

The invention thus also provides a method of combating fungi at a locus infested or liable to be infested therewith, which comprises applying to the locus a compound of formula I.

The invention also provides an agricultural composition comprising a compound of formula I in admixture with an agriculturally acceptable diluent or carrier.

The composition of the invention may of course include more than one compound of the invention.

In addition, the composition can comprise one or more additional active ingredients, for example compounds known to possess plant-growth regulant, herbicidal, fungicidal, insecticidal, acaricidal, antimicrobial or antibacterial properties. Alternatively the compound of the invention can be used in sequence with the other active ingredient.

The diluent or carrier in the composition of the invention can be a solid or a liquid optionally in association with a surface-active agent, for example a dispersing agent, emulsifying agent or wetting agent. Suitable surface-active agents include anionic compounds such as a carboxylate, for example a metal carboxylate of a long chain fatty acid; an *N*-acylsarcosinate; mono- or di-esters of phosphoric acid with fatty alcohol ethoxylates or alkyl phenol ethoxylates or salts of such esters; fatty alcohol sulfates such as sodium dodecyl sulfate, sodium octadecyl sulfate or sodium cetyl sulfate; ethoxylated fatty

alcohol sulfates; ethoxylated alkylphenol sulfates; lignin sulfonates; petroleum sulfonates; alkyl-aryl sulfonates such as alkyl-benzene sulfonates or lower alkylnaphthalene sulfonates, e.g. butyl-naphthalene sulfonate; salts of sulfonated naphthalene-formaldehyde condensates; salts of sulfonated phenol-formaldehyde condensates; or more complex sulfonates such as
5 the amide sulfonates, e.g. the sulfonated condensation product of oleic acid and *N*-methyl taurine; the dialkyl sulfosuccinates, e.g. the sodium sulfonate of dioctyl succinate; acid derivatives of alkyl glycosides and alkylpolyglycosides materials and their metal salts, e.g. alkyl polyglycoside citrate or tartrate materials; or mono-, di- and tri-alkyl esters of citric acid and their metal salts.

10

Nonionic agents include condensation products of fatty acid esters, fatty alcohols, fatty acid amides or fatty-alkyl- or alkenyl-substituted phenols with ethylene and/or propylene oxide; fatty esters of polyhydric alcohol ethers, e.g. sorbitan fatty acid esters; condensation
products of such esters with ethylene oxide, e.g. polyoxyethylene sorbitan fatty acid esters;
15 alkyl glycosides, alkyl polyglycoside materials; block copolymers of ethylene oxide and propylene oxide; acetylenic glycols such as 2,4,7,9-tetramethyl-5-decyne-4,7-diol, ethoxylated acetylenic glycols; acrylic based graft copolymers; alkoxylated siloxane surfactants; or imidazoline type surfactants, e.g. 1-hydroxyethyl-2-alkylimidazoline.

20 Examples of a cationic surface-active agent include, for instance, an aliphatic mono-, di-, or polyamine as an acetate, naphthenate or oleate; an oxygen-containing amine such as an amine oxide, polyoxyethylene alkylamine or polyoxypropylene alkylamine; an amide-linked amine prepared by the condensation of a carboxylic acid with a di- or polyamine; or a quaternary ammonium salt.

25

The compositions of the invention can take any form known in the art for the formulation of agrochemicals, for example, a solution, an aerosol, a dispersion, an aqueous emulsion, a microemulsion, a dispersible concentrate, a dusting powder, a seed dressing, a fumigant, a smoke, a dispersible powder, an emulsifiable concentrate, granules or an impregnated strip.
30 Moreover it can be in a suitable form for direct application or as a concentrate or primary composition which requires dilution with a suitable quantity of water or other diluent before application.

A dispersible concentrate comprises a compound of the invention dissolved in one or more water miscible or semi-water miscible solvents together with one or more surface activeand/or polymeric material. Addition of the formulation to water results in the crystallisation of the active ingredient, the process being controlled by the surfactants and/or polymers resulting in a fine dispersion.

A dusting powder comprises a compound of the invention intimately mixed and ground with a solid pulverulent diluent, for example, kaolin.

An emulsifiable concentrate comprises a compound of the invention dissolved in a water-immiscible solvent which forms an emulsion or microemulsion on addition to water in the presence of an emulsifying agent.

A granular solid comprises a compound of the invention associated with similar diluents to those that may be employed in dusting powders, but the mixture is granulated by known methods. Alternatively it comprises the active ingredient absorbed or coated on a pre-formed granular carrier, for example, Fuller's earth, attapulgit, silica or limestone grit.

Wettable powders, granules or grains usually comprise the active ingredient in admixture with suitable surfactants and an inert powder diluent such as clay or diatomaceous earth.

Another suitable concentrate is a flowable suspension concentrate which is formed by grinding the compound with water or other liquid, surfactants and a suspending agent.

The concentration of the active ingredient in the composition of the present invention, as applied to plants is preferably within the range of 0.0001 to 1.0 per cent by weight, especially 0.0001 to 0.01 per cent by weight. In a primary composition, the amount of active ingredient can vary widely and can be, for example, from 5 to 95 per cent by weight of the composition.

The invention is generally applied to seeds, plants or their habitat. Thus, the compound can be applied directly to the soil before, at or after drilling so that the presence of active compound in the soil can control the growth of fungi which may attack seeds. When the soil is treated directly the active compound can be applied in any manner which allows it to be

intimately mixed with the soil such as by spraying, by broadcasting a solid form of granules, or by applying the active ingredient at the same time as drilling by inserting it in the same drill as the seeds. A suitable application rate is within the range of from 5 to 1000 g per hectare, more preferably from 10 to 500 g per hectare.

5

Alternatively the active compound can be applied directly to the plant by, for example, spraying or dusting either at the time when the fungus has begun to appear on the plant or before the appearance of fungus as a protective measure. In both such cases the preferred mode of application is by foliar spraying. It is generally important to obtain good control of
10 fungi in the early stages of plant growth, as this is the time when the plant can be most severely damaged. The spray or dust can conveniently contain a pre- or post-emergence herbicide if this is thought necessary. Sometimes, it is practicable to treat the roots, bulbs, tubers or other vegetative propagule of a plant before or during planting, for example, by dipping the roots in a suitable liquid or solid composition. When the active compound is
15 applied directly to the plant a suitable rate of application is from 0.025 to 5 kg per hectare, preferably from 0.05 to 1 kg per hectare.

In addition, the compounds of the invention can be applied to harvested fruits, vegetables or seeds to prevent infection during storage.


20

In addition, the compounds of the invention can be applied to plants or parts thereof which have been genetically modified to exhibit a trait such as fungal and/or herbicidal resistance.

In addition the compounds of the invention can be used to treat fungal infestations in timber
25 and in public health applications. Also the compounds of the invention can be used to treat insect and fungus infestations in domestic and farm animals.


Compounds of the invention may be prepared, in known manner, in a variety of ways.

30 Compounds of formula Iai, i.e. compounds of general formula I where L is $-\text{CH}(\text{R}^1)\text{NHCH}(\text{R}^2)-$, may be prepared according to reaction scheme 1. Compounds of formula II or their hydrochloride salts can be condensed with compounds of formula III and the intermediate reduced with a suitable reagent such as sodium cyanoborohydride to give compounds of formula Iai.

Scheme 1


Compounds of formula II may be prepared by methods described in international application
 5 PCT/GB/99/00304.

Compounds of formula Iai may also be prepared by reacting compounds of formula IV with
 compounds of formula V in the same manner as above (Scheme 2).


Scheme 2

10

Compounds of formula Iaii, i.e. compounds of general formula I where L is
 -CH(R¹)N(R³)CH(R²)- and R³ is not hydrogen, may be prepared by reacting compounds of
 formula Iai with a base and R³Q, where Q is a leaving group such as a halogen. A suitable
 base is triethylamine (Scheme 3).


15 Scheme 3

Compounds of formula Ib, i.e. compounds of general formula I where L is
 -N(R³)N(R⁴)C(=X)-, may be prepared according to reaction scheme 4 by reacting
 20 compounds of formula VI with compounds of formula VII, where Q is a leaving group such
 as halogen, preferably chlorine. A preferred base is triethylamine.

Scheme 4


Compounds of formula Ic, i.e. compounds of general formula I where L is

- 5 -C(=O)N(R³)CH(R¹)-, may be prepared by radical bromination of compounds of formula VIII, followed by reaction of these intermediates with compounds of formula IX according to scheme 5. Preferred reaction conditions are irradiation of a solution of VIII in carbon tetrachloride in the presence of *N*-bromosuccinimide and a catalytic amount of 2,2'-azobisisobutyronitrile, followed by addition of IX..

10 **Scheme 5**

Compounds of formula Id, i.e. compounds of general formula I where L is -CH(R¹)O(C=O)-, may be prepared according to reaction scheme 6 by formation of the cesium salt of


- 15 compounds of formula XI, followed by reaction with compounds of formula X where Q is a suitable leaving group, such as chlorine.

Scheme 6

- 20 Compounds of formula Ie, i.e. compounds of general formula I where L is -CH(R¹)OCH(R²)-, may be prepared by reaction of compounds of formula XII with a

suitable base such as sodium hydride, followed by reaction of the resulting anion with compounds of formula X, where Q is a suitable leaving group such as halogen, according to reaction scheme 7.


Scheme 7




Compounds of formula If, i.e. compounds of general formula I where L is $-\text{N}(\text{R}^3)\text{C}(=\text{X})\text{N}(\text{R}^4)-$ and X is O or S, may be prepared according to reaction scheme 8 by reaction of compounds of formula XIII with compounds of formula XIV, where X is O or S, followed by the addition of compounds of formula XV. The order of addition of compounds of formulae XIII and XV may be reversed.

10


Scheme 8




15 Compounds of formula Ig, i.e. compounds of general formula I where L is $-\text{C}(\text{R}^1)=\text{C}(\text{R}^2)\text{C}(=\text{O})-$, may be prepared according to reaction scheme 9 by reaction of compounds of formula XVI with compounds of formula XVII in the presence of sodium hydroxide.

Scheme 9

Compounds of formula Ih, i.e. compounds of general formula I where L is $-\text{C}(\text{R}^1)=\text{N}-\text{N}(\text{R}^3)-$, may be prepared by reacting compounds of formula XVIII with compounds of formula XIX according to reaction scheme 10.


Scheme 10

Compounds of formula Ii, i.e. compounds of general formula I where L is $-\text{CH}(\text{R}^1)\text{N}=\text{C}(\text{R}^2)-$, may be prepared according to reaction scheme 11 by reacting compounds of formula XX with a base, followed by reaction with compounds of formula XXI, where Q is a suitable leaving group, preferably chlorine. A suitable base is sodium hydride. Compounds of formula XX are known or can be prepared in a known manner by a skilled chemist.

Scheme 11


Compounds of formula Ij, i.e. compounds of general formula I where L is $-O-N=C(R^1)-$, may be prepared according to reaction scheme 12 by the reaction of compounds of formula XXII with a base, followed by reaction with compounds of formula XXI, where Q is a suitable leaving group, preferably chlorine. A suitable base is sodium hydride.

5 Scheme 12



Compounds of formula XXII may be prepared according to reaction scheme 13.


Scheme 13



10

Compounds of formula Imi, i.e. compounds of general formula I where L is $-O-NHC(=O)-$, may be prepared according to reaction scheme 14 by the reaction of compounds of formula XXIII with compounds of formula XXIV, where Q is a suitable leaving group.

15 Scheme 14




Compounds of formula XXIV can be prepared from the corresponding hydroxy compounds by methods known to the skilled chemist. Compounds of formula XXIV can be isolated and used according to scheme 14 or generated *in situ* and used without isolation. A typical method, known to the skilled chemist, uses carbonyldiimidazole to generate compounds of formula XXIV *in situ*.

20

Compounds of formula XXIII can be prepared according to reaction scheme 15.


Scheme 15



Compounds of formula Imii, i.e. compounds of general formula I where L is

- 5 -O-N(R^3)C(=O)- wherein R^3 is not hydrogen, may be prepared by reaction of compounds of formula Imi with a base, followed by reaction with R^3Q , where Q is a suitable leaving group, such as a halogen. A suitable base is potassium *tert*-butoxide (Scheme 16).

Scheme 16



10

Other methods will be apparent to the chemist skilled in the art, as will be the methods for preparing starting materials and intermediates.

15

Collections of compounds of formula I may also be prepared in a parallel manner, either manually, automatically or semi-automatically. This parallel preparation may be applied to the reaction procedure, work-up or purification of products or intermediates. For a review of such procedures see by S.H. DeWitt in "Annual Reports in Combinatorial Chemistry and Molecular Diversity: Automated synthesis", Volume 1, Verlag Escom 1997, pages 69 to 77.

20

Furthermore, compounds of the formula I may be prepared using solid-supported methods, where the reactants are bound to a synthetic resin. See for example: Barry A. Bunin in "The

Combinatorial Index", Academic Press, 1998 and "The tea-bag method" (Houghten, US 4,631,211; Houghten et al., Proc. Natl. Acad. Sci, 1985, 82, 5131-5135).

5 The invention is illustrated in the following Examples. Structures of isolated, novel compounds were confirmed by NMR and/or other appropriate analyses.

Example 1

N-(2-Chlorobenzyl)-N-{1-[3-chloro-5-(trifluoromethyl)-2-pyridyl]ethyl}amine
(Compound 27)

10 α -Methyl-[3-chloro-5-(trifluoromethyl)-2-pyridyl]methylamine (0.2 g) was dissolved in trimethylorthoformate (10 ml) and triethylamine (0.22 ml) was added. After 5 minutes 2-chlorobenzaldehyde (0.26 g) was added and the resulting mixture stirred for 3.5 hours at room temperature to give a precipitate. Sodium cyanoborohydride (1.5 ml, 0.1M solution in tetrahydrofuran) and acetic acid (0.1 ml) were then added and the mixture stirred for 16
15 hours at room temperature. Brine (5 ml) and water (10 ml) were then added and the mixture stirred for 20 minutes. The phases were separated and the organic phase evaporated. The residue was purified by silica gel chromatography to give the title product, m.p. 117 °C.

Example 2

20 N-{[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl}-N-[1-(3,4-difluorophenyl)-ethyl]amine
(Compound 23)


Triethylamine (0.08 ml) and 1-(3,4-difluorophenyl)-1-ethanamine (0.11 g) were dissolved in trimethylorthoformate (10 ml). 3-Chloro-(5-trifluoromethyl)-pyridine-2-carboxaldehyde (0.15 g) was added and the solution stirred for 4 hours at room temperature. Sodium
25 cyanoborohydride (1 ml, 0.1M solution in tetrahydrofuran) and acetic acid (0.07 ml) were then added and the mixture stirred for 16 hours at room temperature. Brine (5 ml) and water (10 ml) were then added and the mixture stirred for 20 minutes. The phases were separated and the organic phase evaporated. The crude material was purified by silica gel chromatography to give the title product, ¹H N.M.R (CDCl₃) δ (ppm) 1.4 (3H, d), 2.6 (1H,
30 broad s), 3.8 (1H, q), 3.9 (1H, s), 7.1-7.3 (3H, m), 7.9 (1H, s) and 8.8 (1H, s).

Example 3

Ethyl 2-[acetyl(benzyl)amino]-2-[3-chloro-5-(trifluoromethyl)-2-pyridyl]acetate (Compound 4)

To a solution of compound 1 (0.6 mmol) in diethyl ether was added triethylamine (0.7 mmol) followed by acetyl chloride in diethyl ether (0.7 mmol). The mixture was stirred for two hours at room temperature before the addition of hydrochloric acid (8 ml, 2M). The organic phase was isolated, washed with sodium bicarbonate (10ml), dried over magnesium sulfate and evaporated to yield the title compound, ¹H N.M.R (CDCl₃) (ppm) δ 1.2 (3H, t), 2.3 (3H, s), 4.2 (2H, q), 4.8 (2H, q), 6.8-7.1 (6H, m), 7.5 (1H, s) and 8.5 (1H, s).



The following compounds of formula Iz (see Table A), i.e. compounds of general formula I where A¹ is 3-Cl-5-CF₃-2-pyridyl and L is -CH(R¹)N(R³)CH(R²)-, may be prepared by methods analogous to those of Examples 1, 2 and 3. The amine starting materials were




(Iz)

Table A

Cmp	R ¹	R ²	R ³	A ²	m.p./°C
1	EtOC(=O)-	H	H	phenyl	oil
2	EtOC(=O)-	H	H	2-Cl-phenyl	oil
3	EtOC(=O)-	H	H	3,4-methylenedioxyphenyl	oil
4	EtOC(=O)-	H	MeC(=O)-	phenyl	oil
5	EtOC(=O)-	H	MeOCH ₂ C(=O)-	phenyl	oil
6	EtOC(=O)-	H	MeOC(=O)-C(=O)-	phenyl	104-7
7	EtOC(=O)-	H	MeC(=O)-	2-Cl-phenyl	77-81
8	EtOC(=O)-	H	MeOCH ₂ C(=O)-	2-Cl-phenyl	oil
9	EtOC(=O)-	H	MeOC(=O)-C(=O)-	2-Cl-phenyl	128-31
10	EtOC(=O)-	H	MeC(=O)-	3,4-methylenedioxyphenyl	oil
11	EtOC(=O)-	H	MeOCH ₂ C(=O)-	3,4-methylenedioxyphenyl	oil
12	EtOC(=O)-	H	MeOC(=O)-C(=O)-	3,4-methylenedioxyphenyl	106-9
13	H	MeOC(=O)CH ₂ -	H	phenyl	oil

Cmp	R ¹	R ²	R ³	A ²	m.p./°C
14	H	EtOC(=O)CH ₂ -	H	phenyl	oil
15	H	H	H	phenyl	oil
16	H	H	H	2-Cl-6-F-phenyl	oil
17	H	Me	H	2-Cl-phenyl	oil
18	H	Me	H	2,6-diF-phenyl	oil
19	H	Me	H		oil
20	H	Me	H	4-tolyl	oil
21	H	H	H	2,5-diF-phenyl	oil
22	H	Me	H	4-NO ₂ -phenyl	oil
23	H	Me	H	3,4-diF-phenyl	oil
24	H	H	H	2-Cl-phenyl	oil
25	H	H	H	4-PhO-phenyl	oil
26	H	H	H	2-NO ₂ -phenyl	oil
27	Me	H	H	2-Cl-phenyl	117
28	Me	H	H	2-NO ₂ -phenyl	136
29	H	Me	H	phenyl	oil
30	H	Me	H	3-CF ₃ O-phenyl	oil
31	H	Me	H	4-CF ₃ O-phenyl	oil
32	H	Me	H		oil
33	H	Me	H	4-Cl-phenyl	oil
34	H	Me	H	4-Br-phenyl	oil
35	Me	H	H	cyclohexyl	oil
36	Me	H	H	2-F-phenyl	oil
37	Me	H	H	4-Cl-phenyl	oil
38	Me	H	H	2,5-diMeO-phenyl	oil
39	Me	H	H	2-Cl-6-F-phenyl	oil
40	Me	H	H	2-Br-phenyl	oil
41	Me	H	H	3-CF ₃ O-phenyl	oil
42	Me	H	H	4-MeS-phenyl	oil

Cmp	R ¹	R ²	R ³	A ²	m.p./°C
43	Me	H	H	2,5-xylyl	oil
44	H	H	H	cyclohexyl	oil
45	H	H	H	3-Br-phenyl	oil
46	H	H	H	4-Me ₂ N-phenyl	oil
47	H	H	H	4-Cl-phenyl	oil
48	H	H	H	2-F-phenyl	oil
49	H	H	H	2,5-diMeO-phenyl	oil
50	H	H	H	2-Br-phenyl	oil
51	H	H	H	4-NO ₂ -phenyl	oil
52	H	H	H	2,5-xylyl	oil
53	H	Me	H		oil
54	H	H	H	pentaF-phenyl	oil

The ¹H N.M.R. or mass spectral data of those compounds in Table A which were not solid at room temperature are presented below.

5 Compound 1

¹H N.M.R (CDCl₃) δ (ppm) 1.2 (3H, t), 2.9 (1H, broad s), 3.8 (1H, q), 4.2 (2H, m), 5.0 (1H, s), 7.4-7.2 (5H, m), 7.9 (1H, s), 8.7 (1H, s).

Compound 2

10 ¹H N.M.R (CDCl₃) δ (ppm) 1.2 (3H, t), 3.1 (1H, broad s), 4.0 (2H, q), 4.2 (2H, m), 5.1 (1H, s), 7.5-7.2 (4H, m), 8.0 (1H, s), 8.7 (1H, s).

Compound 3

15 ¹H N.M.R (CDCl₃) δ (ppm) 1.2 (3H, t), 2.4 (1H, broad s), 3.8 (2H, q), 4.2 (2H, m), 5.0 (1H, s), 5.9 (2H, s), 6.74 (1H, d), 6.76 (1H, s), 6.83 (1H, s), 7.9 (1H, s), 8.7 (1H, s).

Compound 4

^1H N.M.R (CDCl_3) δ (ppm) 1.2 (3H, t), 2.3 (3H, s), 4.2 (2H, q), 4.8 (2H, q), 6.8-7.1 (6H, m), 7.5 (1H, s), 8.5 (1H, s).

5 Compound 5

m/z (APCI) 445 ($\text{M}+\text{H}$) $^+$.

Compound 8

m/z (APCI) 479 ($\text{M}+\text{H}$) $^+$.

10

Compound 10

m/z (APCI) 487 (M^+)

Compound 1115

m/z (APCI) 459 ($\text{M}+\text{H}$) $^+$.

Compound 13

^1H N.M.R (CDCl_3) δ (ppm) 2.7 (1H, dd), 2.9 (1H, dd), 3.6 (3H, s), 3.9 (2H, s), 4.2 (1H, m), 7.3 (5H, m), 7.8 (1H, s), 8.8 (1H, m).

20

Compound 14

^1H N.M.R (CDCl_3) δ (ppm) 1.2 (3H, t), 2.7 (1H, dd), 2.8 (1H, dd), 3.9 (2H, s), 4.1 (2H, q), 4.2 (1H, m), 7.2-7.4 (5H, m), 7.8 (1H, s), 8.8 (1H, s).

25 Compound 15

^1H N.M.R (CDCl_3) δ (ppm) 4.2 (2H, s), 5.3 (2H, s), 7.3 (6H, m), 8.8 (1H, s), 8.9 (1H, s).

Compound 16

^1H N.M.R (CDCl_3) δ (ppm) 2.7 (1H, broad s), 4.05 (4H, s), 6.9-7.2 (3H, m), 7.8 (1H, s), 8.6 (1H, s).

30

Compound 17

¹H N.M.R (CDCl₃) δ(ppm) 1.4 (3H, d), 2.5 (1H, broad s), 3.9 (2H, m), 4.3 (1H, q), 7.1-7.3 (3H, m) 7.5 (1H, m) 7.8 (1H, s), 8.7 (1H, s).

5 Compound 18

¹H N.M.R (CDCl₃) δ(ppm) 1.5 (3H, d), 2.6 (1H, broad s), 3.8 (1H, m), 4.0 (1H, m) 4.3 (1H, q), 6.8 (2H, m) 7.1 (1H, m) 7.8 (1H, s) 8.6 (1H, s).

Compound 19

10 ¹H N.M.R (CDCl₃) δ(ppm) 1.4 (3H, d) 2.6 (1H, broad s), 3.8 (1H, q), 4.0 (2H, s), 4.3 (4H, s) 6.8 (2H, s), 6.9 (1H, s), 7.9 (1H, s), 8.7 (1H, s).

Compound 20

15 ¹H N.M.R (CDCl₃) δ(ppm) 1.5 (3H, d), 2.4 (3H, s), 2.8 (1H, broad s), 3.8 (1H, q), 4.0 (2H, m), 7.2 (2H, d), 7.3 (2H, d), 7.8 (1H, s), 8.7 (1H, s).

Compound 21

20 ¹H N.M.R (CDCl₃) δ(ppm) 2.5 (1H, broad s), 4.0 (2H, s), 4.1 (2H, s), 6.8 (2H, m), 7.2 (1H, m), 7.8 (1H, s), 8.6 (1H, s).

Compound 22

¹H N.M.R (CDCl₃) δ(ppm) 1.4 (3H, d), 2.5 (1H, broad s), 3.86 (2H, s), 3.9 (1H, m), 7.5 (2H, d), 7.8 (1H, s), 8.1 (2H, d), 8.7 (1H, s).

25 Compound 23

¹H N.M.R (CDCl₃) δ(ppm) 1.4 (3H, d), 2.6 (1H, broad s), 3.8 (1H, q), 3.9 (1H, s), 7.1-7.3 (3H, m), 7.9 (1H, s), 8.8 (1H, s).

Compound 24

30 ¹H N.M.R (CDCl₃) δ(ppm) 4.1 (4H, m), 4.4 (1H, dd), 4.6 (1H, dd), 6.5 (1H, broad s), 7.2-7.4 (5H, m), 7.8 (1H, s), 8.6 (1H, s).

Compound 25

^1H N.M.R (CDCl_3) δ (ppm) 3.9 (1H, dd), 4.2 (1H, dd), 4.4 (2H, m), 6.0 (1H, broad s), 6.9-7.0 (5H, m), 7.2-7.4 (4H, m), 8.0 (1H, s), 8.7 (1H, s).

5 Compound 26

^1H N.M.R (CDCl_3) δ (ppm) 4.3 (2H, m), 4.7 (2H, m), 7.0 (1H, broad s), 7.6 (1H, m), 7.7 (2H, m), 7.9 (1H, s), 8.2 (1H, m), 8.6 (1H, s).

Compound 29

10 ^1H N.M.R (CDCl_3) δ (ppm) 1.5 (3H, s), 2.6 (1H, broad s), 3.9 (1H, q), 4.0 (2H, s), 7.2-7.4 (5H, m), 7.8 (1H, s), 8.7 (1H, s).

Compound 30

15 ^1H N.M.R (CDCl_3) δ (ppm) 1.4 (3H, d), 2.6 (1H, broad s), 3.8 (1H, q), 3.9 (2H, s), 4.0 (2H, s), 7.0 (1H, m), 7.2-7.3 (3H, m), 7.8 (1H, s), 8.7 (1H, s).

Compound 31

^1H N.M.R (CDCl_3) δ (ppm) 1.5 (3H, d), 2.7 (1H, broad s), 3.8 (1H, q), 6.5 (1H, m), 7.1 (2H, d), 7.4 (2H, d), 7.9 (1H, s), 8.8 (1H, s).

20

Compound 32

^1H N.M.R (CDCl_3) δ (ppm) 1.5 (3H, d), 1.8 (4H, m), 2.8 (4H, m), 3.8 (1H, q), 4.0 (2H, s), 7.1 (3H, m), 7.9 (1H, s), 8.8 (1H, s).

25 Compound 33

^1H N.M.R (CDCl_3) δ (ppm) 1.42 (3H, d), 2.62 (1H, broad, s), 3.83 (1H, q), 3.92 (2H, s), 7.3 (4H, s), 7.82 (1H, s); 8.75 (1H, s).

Compound 34

30 ^1H N.M.R (CDCl_3) δ (ppm) 1.42 (3H, d), 2.58 (1H, s, broad), 3.82 (1H, q), 3.92 (2H, s), 7.25 (2H, m), 7.45 (2H, m), 7.85 (1H, s), 8.72 (1H, s).

Compound 35

^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ selected peaks at 1.38 (3H, d), 4.35 (1H, q), 7.85 (1H, s), 8.75 (1H, s).

5 Compound 36

^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.38 (3H, d), 2.35 (1H, broad, s), 3.68 (2H, m), 4.42 (1H, q), 6.95 (1H, m), 7.05 (1H, m), 7.16 (1H, m), 7.32 (1H, m), 7.82 (1H, s), 8.75 (1H, s).

Compound 37

10 ^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ selected peaks at 1.38 (3H, d), 3.56 (2H, m), 4.4 (1H, q), 7.88 (1H, s), 8.78 (1H, s).

Compound 39

15 ^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.3 (3H, d), 2.7 (1H, broad, s), 3.8 (2H, s), 4.4 (1H, q), 6.75 (1H, m), 6.98 (2H, m), 7.72 (1H, s), 8.55 (1H, s).

Compound 40

^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.41 (3H, d), 2.3 (1H, broad, s), 3.72 (2H, m), 4.25 (1H, q), 7.05-7.5 (4H, m), 7.85 (1H, s), 8.75 (1H, s).

20

Compound 41

^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.38 (3H, d), 2.4 (1H, s, broad), 3.6 (2H, m), 4.4 (1H, q), 7.05-7.5 (4H, m), 7.88 (1H, s), 8.78 (1H, s).

25 Compound 42

^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.38 (3H, d), 2.48 (3H, s), 3.6 (2H, m), 4.45 (1H, q), 7.2 (4H, m), 7.88 (1H, s), 8.78 (1H, s).

Compound 43

30 ^1H N.M.R (CDCl_3) $\delta(\text{ppm})$ 1.4 (3H, d), 2.25 (3H, s), 2.32 (3H, s), 2.5 (1H, broad, s), 3.58 (2H, m), 4.48 (1H, q), 6.9-7.08 (3H, m), 7.9 (1H, s), 8.78 (1H, s).

Compound 44

^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 2.53 (2H, d), 4.1 (2H, s), 7.85 (1H, s), 8.75 (1H, s).

5 Compound 45

^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 3.85 (1H, s), 4.1 (1H, s), 7.9 (1H, s), 8.75 (1H, s).

Compound 46

10 ^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 7.8 (1H, s), 8.68 (1H, s), 3.5 (1H, m), 3.9 (2H, m), 4.1 (1H, m).

Compound 47

15 ^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 3.86 (2H, s), 4.08 (2H, s), 7.90 (1H, s), 8.72 (1H, s).

Compound 48

^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 2.65 (1H, s, broad), 3.98 (2H, s), 4.15 (2H, s), 7.9 (1H, s), 8.75 (1H, s).

20 Compound 49

^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 3.80 (3H, s), 3.85 (3H, s), 6.88 (2H, m), 7.06 (1H, m), 7.90 (1H, s), 8.72 (1H, s).

Compound 50

25 ^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 4.0 (2H, s), 4.1 (2H, s), 7.85 (1H, s), 8.70 (1H, s).

Compound 51

30 ^1H N.M.R (CDCl_3) δ (ppm) selected peaks at 2.65 (1H, broad, s), 3.83 (2H, s), 4.0 (2H, s), 7.8 (1H, s), 8.65 (1H, s).

Compound 52

$^1\text{H N.M.R}$ (CDCl_3) $\delta(\text{ppm})$ selected peaks at 3.83 (2H, s), 4.18 (2H, s), 7.9 (1H, s), 8.75 (1H, s).

5 Compound 53

$^1\text{H N.M.R}$ (CDCl_3) $\delta(\text{ppm})$ 1.4 (3H, d), 2.5 (1H, broad s), 3.8 (1H, q), 3.9 (2H, s), 6.0 (2H, s), 6.8-6.9 (3H, m), 7.9 (1H, s), 8.7 (1H, s).

Compound 54

10 $^1\text{H N.M.R}$ (CDCl_3) $\delta(\text{ppm})$ selected peaks at 7.75 (1H, s), 8.80 (1H, s).


Example 4

N'-1-[3-Chloro-5-(trifluoromethyl)-2-pyridyl]-2,6-dichloro-1-benzenecarbohydrazide

(Compound 102)

15 3-Chloro-5-(trifluoromethyl)pyrid-2-ylhydrazine (0.32 g) was dissolved in dichloromethane (7 ml) and treated dropwise with 2,6-dichlorobenzoyl chloride (0.31 g) in dichloromethane (2 ml). Triethylamine (0.15 g) was then added and the reaction stirred at room temperature overnight. The organic solution was washed sequentially with sodium bicarbonate solution and brine and evaporated to give a solid. The residue was purified by trituration
20 (dichloromethane) to give the title compound, m.p. 212-5 °C.

The following compounds of formula Iy (see Table B), i.e. compounds of general formula I where L is $-\text{N}(\text{R}^3)\text{NHC}(=\text{O})-$, may be prepared by methods analogous to those of Example 4.



(Iy)

Table B

Cmp	A ¹	R ³	A ²	m.p./°C
101	3-Cl-5-CF ₃ -phenyl	H	2-Cl-phenyl	168-70
102	3-Cl-5-CF ₃ -phenyl	H	2,6-diCl-phenyl	212-5


Cmp	A ¹	R ³	A ²	m.p./°C
103	3-Cl-5-CF ₃ -phenyl	H	2-NO ₂ -phenyl	182-3
104	3-Cl-5-CF ₃ -phenyl	H	2,6-diMeO-phenyl	204-6
105	3-Cl-5-CF ₃ -phenyl	H	2-tolyl	168-9
107	3-Cl-5-CF ₃ -phenyl	H	cyclopropyl	152-4
108	3-Cl-5-CF ₃ -phenyl	H	cyclohexyl	111-4
109	3-Cl-5-CF ₃ -phenyl	Me	2,6-diCl-phenyl	219-20
110	3-Cl-5-CF ₃ -phenyl	Me	2-NO ₂ -phenyl	198-9
111	3-Cl-5-CF ₃ -phenyl	Me	2,6-diMeO-phenyl	234-6
112	3-Cl-5-CF ₃ -phenyl	Me	2-tolyl	202-4
113	3-Cl-5-CF ₃ -phenyl	Me	2-Cl-6-F-phenyl	207-8
115	3-Cl-5-CF ₃ -phenyl	Me	cyclopropyl	159-60
116	3-Cl-5-CF ₃ -phenyl	Me	cyclohexyl	216-9
117	5-Cl-3-CF ₃ -phenyl	H	2,6-diCl-phenyl	199-203
118	5-Cl-3-CF ₃ -phenyl	H	2-NO ₂ -phenyl	156-8
119	5-Cl-3-CF ₃ -phenyl	H	2,6-diMeO-phenyl	194-5
120	5-Cl-3-CF ₃ -phenyl	H	2-tolyl	180-1
121	5-Cl-3-CF ₃ -phenyl	H	2-Cl-6-F-phenyl	173-5
123	5-Cl-3-CF ₃ -phenyl	H	cyclopropyl	143-5
124	5-Cl-3-CF ₃ -phenyl	H	cyclohexyl	121
125	3-Cl-5-CF ₃ -phenyl	H	2,3,6-triF-phenyl	154-6
126	3-Cl-5-CF ₃ -phenyl	H	2-Cl-6-F-phenyl	192

Example 5**N-2-(Phenylethyl)-3-chloro-5-(trifluoromethyl)-2-pyridinecarboxamide****(Compound 206)**

- 5 3-Chloro-(5-trifluoromethyl)pyridine-2-carboxaldehyde (0.15 g) was dissolved in carbon tetrachloride (10 ml). 2,2'-Azobisisobutyronitrile (0.002 g) and *N*-bromosuccinimide (0.16 g) were added and the mixture was heated to reflux using a sun lamp. After 45 minutes the solution was cooled down to 0 °C. (R)-(+)- α -methylbenzylamine (0.09 g) in carbon tetrachloride (0.3 ml) was added and stirred for 20 minutes at 0°C, then for 3 hours at room
- 10 temperature. The mixture was diluted with dichloromethane and washed with water. The



organic layer was isolated, dried over magnesium sulphate and evaporated to give the crude compound. The crude material was purified by silica gel chromatography to give the title product, m.p. 88 °C.


- 5 The following compounds of formula Ix (see Table C), i.e. compounds of general formula I where A¹ is 3-Cl-5-CF₃-2-pyridyl and L is -C(=O)NHCH(R¹)-, may be prepared by methods analogous to those of Example 5.



(Ix)

Table C

Cmp	R ¹	A ²	m.p.(°C)
201	H	2,6-diF-phenyl	137
202	Me	2,6-diF-phenyl	97
203	H	2-Cl-phenyl	100-7
204	H	2,6-diCl-phenyl	114-6
205	Me	2-Cl-phenyl	120
206	Me	phenyl	88
207	Me	4-Cl-phenyl	129
208	Me	4-Br-phenyl	139
209	Me	3,4-diF-phenyl	127
210	Me		123
211	Me	4-CF ₃ O-phenyl	95
212	Me	3-CF ₃ O-phenyl	114
213	Me		125

Cmp	R ¹	A ²	m.p.(°C)
214	Me		129
215	H	4-tolyl	113


Example 6

[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl 2-chlorobenzoate

Compound 301

- 5 To a solution of 2-chlorobenzoic acid (0.1 g) in dimethylformamide was added cesium carbonate (0.1 g) and the resulting solution was stirred for 1 hour. 3-Chloro-2-(chloromethyl)-5-trifluoromethyl pyridine (0.14 g) was added and stirring was continued for a further 48 hours. The solution was diluted with diethyl ether (10 ml) and washed with water (10 ml). The organic phase was separated, dried and evaporated to give a crude
- 10 product. Silica gel chromatography (petrol/diethyl ether 7:3) gave the title compound, ¹H N.M.R (CDCl₃) δ(ppm) 5.6 (2H, s), 7.3 (1H, m), 7.4 (2H, m) 7.87 (1H, s), 7.88 (1H, d) and 8.8 (1H, s).

- The following compounds of formula Iw (see Table D), i.e. compounds of general formula I
- 15 where A¹ is 3-Cl-5-CF₃-2-pyridyl and L is -CH₂O(C=O)-, may be prepared by methods analogous to those of Example 6.



(Iw)

Table D

Cmp	A ²	m.p./°C
301	2-Cl-phenyl	oil


Cmp	A ²	m.p./°C
302	2,6-diCl-phenyl	93-5

Example 7**[3-Chloro-5-(trifluoromethyl)-2-pyridyl]methyl(2,4-dichlorobenzyl) ether
(Compound 401)**

- 5 To a solution of 2,4-dichlorobenzyl alcohol (0.27 g) in tetrahydrofuran under nitrogen was added sodium hydride (1.1 equivalents) portionwise. The resulting solution was stirred at room temperature for 1 hour before the addition of 3-chloro-2-(chloromethyl)-5-trifluoromethyl pyridine (0.35 g) in tetrahydrofuran dropwise. The solution was then stirred at room temperature for 16 hours. The solution was treated with a tetrahydrofuran/methanol
- 10 solution and the solvent then evaporated. The residue was partitioned between water and ethyl acetate, the organic phase was isolated, washed with brine, dried and evaporated to yield the crude product. Silica gel chromatography (petrol/ethyl acetate 95:5) furnished the title compound, ¹H N.M.R (CDCl₃) δ(ppm) 4.8 (2H, s), 4.9 (2H, s), 7.3 (1H, m), 7.4 (1H, m), 7.5 (1H, m) 8.0 (1H, s) and 8.8 (1H, m).

15

The following compounds of formula Iv (see Table E), i.e. compounds of general formula I where A¹ is 3-Cl-5-CF₃-2-pyridyl and L is -CH₂OCH₂-, may be prepared by methods analogous to those of Example 7.



(Iv)

Table E

Cmp	A ²	m.p./°C
401	2,4-diCl-phenyl	oil
402	2,6-diCl-phenyl	oil

The ¹H N.M.R. data of those compounds in Table E which were not solid at room temperature are presented below.

Compound 402

^1H N.M.R (CDCl_3) δ (ppm) 4.9 (2H, s), 5.0 (2H, s), 7.2 (1H, m), 7.3 (2H, m), 8.0 (1H, s), 8.8 (1H, s).


5

Example 8

N-[2-Chloro-5-(trifluoromethyl)-2-pyridyl]-*N'*-(2,6-dichlorophenyl)urea
(Compound 501)

A solution of triphosgene (1.1 g) in dichloromethane (20 ml) was added over 30 minutes at room temperature to a stirred solution of 2-amino-3-chloro-5-(trifluoromethyl)pyridine (1.96 g) and triethylamine (2 ml) in dichloromethane (35 ml). After 15 minutes a solution of 2,6-dichloroaniline (1.62 g) and triethylamine (2 ml) in dichloromethane (20 ml) was added rapidly and the resulting mixture stirred for 30 minutes before solvent evaporation. The residue was suspended in ethyl acetate and the solid filtered off. The filtrate was washed with potassium hydrogen sulfate solution, sodium bicarbonate solution and then brine. Drying (MgSO_4) and solvent evaporation yielded the crude product, which was purified by silica gel chromatography to give the title compound, m.p. 155-8 °C.

The following compounds of formula Iu (see Table F), i.e. compounds of general formula I where A^1 is 3-Cl-5- CF_3 -2-pyridyl and L is $-\text{NHC}(=\text{O})\text{NH}-$, may be prepared by methods analogous to those of Example 8.



(Iu)

Table F

Cmp	A^2	m.p./°C
501	2,6-diCl-phenyl	155-8
502	phenyl	173-5
503	2- NO_2 -phenyl	178-80

Example 93-[3-Chloro-5-(trifluoromethyl)-2-pyridyl]-1-(2-nitrophenyl)-2-propen-1-one
(Compound 601)

- 5 Sodium hydroxide (0.55 g) was dissolved in water (5 ml) and the resulting solution was diluted with ethanol (3 ml). 2-Nitroacetophenone (1.8 g) was added at 20°C, and the solution was stirred for 5 minutes. 3-Chloro-5-(trifluoromethyl)pyridine-2-carboxaldehyde (2.25 g) was added and stirring was continued for 16 hours. The solution was acidified with acetic acid, the organic layer separated, dried over magnesium sulfate, filtered and
10 evaporated to give a brown oil. Silica gel column chromatography, followed by recrystallisation (petrol) afforded the title compound, 88-9 °C.

Example 103-Chloro-5-(trifluoromethyl)-2-pyridinecarbaldehyde 2-(2-nitrophenyl)hydrazone
(Compound 701)


- 15 A mixture of 3-chloro-5-(trifluoromethyl)pyridine-2-carboxaldehyde (1.05 g) and 2-nitrophenylhydrazine (0.76 g) in ethanol (75 ml) was heated at reflux for 2.5 hours and then allowed to cool to room temperature overnight. The resulting orange solid was isolated by filtration and recrystallised (petrol) to afford the title compound as a mixture of isomers,
20 m.p. 127-35 °C.

Example 11[3-Chloro-5-(trifluoromethyl)-2-pyridyl][(diphenylmethylene)amino]methyl cyanide
(Compound 803)

- 25 To a suspension of 60% sodium hydride (4.0 g) in dimethylformamide under a nitrogen atmosphere at 0°C was added a solution of [(diphenylmethylene)amino]methyl cyanide (11.1 g) in dimethylformamide dropwise, whilst maintaining the temperature between 0°C and 2°C. The solution was stirred at 0°C for 1 hour. 2,3-Dichloro-5-trifluoromethylpyridine (7 ml) in dimethylformamide was added dropwise and the mixture stirred for 30 minutes at
30 0°C before warming to ambient temperature over 3 hours. The mixture was cooled to 10°C, ethanol (3 ml) added and the solution stirred for 15 minutes. The reaction mixture was then poured as a thin stream into a vigorously stirred mixture of diethyl ether (500ml) and ammonium chloride solution (500 ml). The organic layer was separated and washed with ammonium chloride solution (2x150 ml), dried, filtered and evaporated to give a residue.

Silica gel chromatography (diethyl ether:petrol 5:95) gave the title product as a pale brown solid, m.p. 108-10 °C.

The following compounds of formula It (see Table G), i.e. compounds of general formula I
 5 where A¹ is 3-Cl-5-CF₃-2-pyridyl, L is -CH(R¹)N=C(Ph)-, and A² is phenyl may be prepared by methods analogous to those of Example 11.



(It)

Table G

Cmp	R ¹	m.p./°C
801	CH ₂ CN	82-4
802	CO ₂ Et	oil
803	CN	108-10

10

The mass spectral data of the compound in Table G which was not solid at room temperature is presented below.

Compound 802

15 *m/z* (EI) 373 (M⁺-CO₂Et)

Example 12

1-Biphenyl-1-ethanone O-1-[3-chloro-5-(trifluoromethyl)-2-pyridyl] oxime
 (Compound 936)

20 To 4-acetylbiphenyl oxime (2.5 g) in dimethylformamide (13 ml) under a nitrogen atmosphere was added sodium hydride (0.5 g) portionwise with cooling. The resulting mixture was stirred at 40°C for 20 minutes until the formation of a suspension occurred. 2,3-Dichloro-5-(trifluoromethyl)pyridine (2.5 g) in dimethylformamide (7 ml) was then added and the resulting mixture stirred for 18 hours at room temperature. The mixture was treated


with isopropanol (2 ml) and stirred for 5 minutes before pouring into an ice water/brine solution (300 ml). The resulting precipitate was extracted with diethyl ether (2x125 ml), the organics washed with water, dried, filtered and evaporated to give a solid which on trituration (diethyl ether) and recrystallisation (toluene) yielded the title compound, m.p. 122 °C.

Preparation of Starting Material

4-Acetylbiphenyl Oxime

To a suspension of 4-acetylbiphenyl (25.4 g) in ethanol (230 ml) and water (4 ml) under a nitrogen atmosphere was added hydroxylamine hydrochloride (14.5 g) in water (25 ml) followed by 50% aqueous potassium hydroxide solution (40 g). The resulting mixture was heated at reflux for 18 hours and then cooled to room temperature. The mixture was added to ice/water (500 ml) and acidified to pH 2 to give a precipitate. The solid was filtered off, washed with water until the washings were at pH 6 and then recrystallised from ethanol to give the title compound.


The following compounds of formula Is (see Table H), i.e. compounds of general formula I where L is $-O-N=C(R^1)-$, may be prepared by methods analogous to those of Example 12. The crossed bond in Is indicates that the compounds may exist as cis or trans isomers about the double bond. Isolation of both isomers was possible for some compounds.




(Is)

Table H

Cmp	A ¹	R ¹	A ²	m.p.(°C)
901	3-Cl-5-CF ₃ -2-pyridyl	Me	2-Cl-phenyl	96-7
902	3-Cl-5-CF ₃ -2-pyridyl	H	4-pyridyl	205-6
903	3-Cl-5-CF ₃ -2-pyridyl	Me	3-(2-Cl-4-CF ₃ -phenoxy)phenyl	65-7
904	3-Cl-5-CF ₃ -2-pyridyl	H	2-Cl-6-F-phenyl	119-23
905	3-Cl-5-CF ₃ -2-pyridyl	H	2,6-diCl-phenyl	136-7
906	3-Cl-5-CF ₃ -2-pyridyl	Me	1-Me-2-pyryl	88-9

Cmp	A ¹	R ¹	A ²	m.p.(°C)
907	3-Cl-5-CF ₃ -2-pyridyl	Me	2-tolyl	oil
908	3-Cl-5-CF ₃ -2-pyridyl	Me	2-tolyl	oil
909	3-Cl-5-CF ₃ -2-pyridyl	Me	3-CF ₃ -phenyl	oil
910	3-Cl-5-CF ₃ -2-pyridyl	Me	2-CF ₃ -phenyl	oil
911	3-Cl-5-CF ₃ -2-pyridyl	Me		oil
912	3-Cl-5-CF ₃ -2-pyridyl	tBu	2-pyridyl	oil
913	3-Cl-5-CF ₃ -2-pyridyl	Me	2-thienyl	oil
914	3-Cl-5-CF ₃ -2-pyridyl	H	4-MeO-phenyl	oil
915	3-Cl-5-CF ₃ -2-pyridyl	Me	2,4-xylyl	oil
916	3-Cl-5-CF ₃ -2-pyridyl	H	6-Me-2-pyridyl	oil
917	3-Cl-5-CF ₃ -2-pyridyl	Me	2-naphthyl	oil
918	3-Cl-5-CF ₃ -2-pyridyl	Me	1-naphthyl	oil
919	3-Cl-5-CF ₃ -2-pyridyl	H	4-EtO-phenyl	oil
920	3-Cl-5-CF ₃ -2-pyridyl	H	2-tolyl	oil
921	3-Cl-5-CF ₃ -2-pyridyl	H	2-MeO-phenyl	oil
922	3-Cl-5-CF ₃ -2-pyridyl	Et	phenyl	oil
923	3-Cl-5-CF ₃ -2-pyridyl	H	3-NO ₂ -phenyl	116-8
924	3-Cl-5-CF ₃ -2-pyridyl	CF ₃	2-tolyl	oil
925	3-Cl-5-CF ₃ -2-pyridyl	(EtO) ₂ P(=O)-	cyclohexyl	oil
926	3-Cl-5-CF ₃ -2-pyridyl	-CN	phenyl	76
927	3-Cl-5-CF ₃ -2-pyridyl	Me	phenyl	oil
928	3-Cl-5-CF ₃ -2-pyridyl	H	2-NO ₂ -phenyl	oil
929	3-Cl-5-CF ₃ -2-pyridyl	H	2-Cl-phenyl	87
930	3-Cl-5-CF ₃ -2-pyridyl	H	3-tolyl	oil
931	3-Cl-5-CF ₃ -2-pyridyl	H	3-pyridyl	oil
932	3-Cl-5-CF ₃ -2-pyridyl	H	3-pyridyl	137-8
933	3-Cl-5-CF ₃ -2-pyridyl	H	1-naphthyl	85-90
934	3,5-diCl-2-pyridyl	Me	2-Cl-phenyl	127

Cmp	A ¹	R ¹	A ²	m.p.(°C)
935	3,5-diCl-2-pyridyl	Me	2-Cl-phenyl	70-1
936	3-Cl-5-CF ₃ -2-pyridyl	Me	biphenyl	122
937	3-Cl-5-CF ₃ -2-pyridyl	-CN	2,6-diCl-phenyl	128-9
938	3-Cl-5-CF ₃ -2-pyridyl	-CN	2,6-diCl-phenyl	71-2
939	3-Cl-5-CF ₃ -2-pyridyl	-CN	2-CN-phenyl	139-43
940	3-Cl-5-CF ₃ -2-pyridyl	-CN	2-Cl-phenyl	83-4
941	3-Cl-5-CF ₃ -2-pyridyl	-CN	2-Cl-phenyl	88
942	3-Cl-5-CF ₃ -2-pyridyl	Me	2-MeSO ₂ -phenyl	oil
943	3-Cl-5-CF ₃ -2-pyridyl	Ph	2-naphthyl	oil
944	3-Cl-5-CF ₃ -2-pyridyl	Me	6-MeO-2-naphthyl	oil
945	3-Cl-5-CF ₃ -2-pyridyl	Me	4-F-1-naphthyl	oil
946	3-Cl-5-CF ₃ -2-pyridyl	Me	4-cyclohexyl-phenyl	oil
947	3-Cl-5-CF ₃ -2-pyridyl	Me		oil
948	3-Cl-5-CF ₃ -2-pyridyl	Pr	4-Cl-phenyl	oil
949	3-Cl-5-CF ₃ -2-pyridyl	Me	cyclohexyl	oil
950	3-Cl-5-CF ₃ -2-pyridyl	Me	4-PhO-phenyl	oil
951	3-Cl-5-CF ₃ -2-pyridyl	Me	2,5-diMe-3-furyl	oil
952	3-Cl-5-CF ₃ -2-pyridyl	Me	3,5-diMe-isothiazol-4-yl	oil
953	3-Cl-5-CF ₃ -2-pyridyl	Et	2,4-diCl-phenyl	oil
954	3-Cl-5-CF ₃ -2-pyridyl	Me	2,3-diCl-phenyl	oil
955	3-Cl-5-CF ₃ -2-pyridyl	-CN	2-pyridyl	oil
956	3-Cl-5-CF ₃ -2-pyridyl	CF ₃	2-thienyl	oil
957	3-Cl-5-CF ₃ -2-pyridyl	Me	4-pyridyl	oil
958	3-Cl-5-CF ₃ -2-pyridyl	4-Cl-phenyl	4-Cl-phenyl	oil

The ¹H N.M.R or mass spectral data of those compounds in Table H which were not solid at room temperature are presented below.

Compound 907

^1H N.M.R (CDCl_3) δ (ppm) 2.4 (6H, s), 7.2-7.4 (4H, m), 7.95 (1H, s), 8.45 (1H, s).

Compound 908

5 ^1H N.M.R (CDCl_3) δ (ppm) 2.3 (3H), 2.4 (3H), 7.1 (1H), 7.3 (3H, m), 7.8 (1H), 8.45 (1H).

Compound 909

m/z (EI) 382 (M^+).

10 Compound 910

^1H N.M.R (CDCl_3) δ (ppm) 2.5 (3H), 7.45 (1H, d), 7.5-7.7 (2H, m), 7.75 (1H, d), 8.0 (1H, d), 8.5 (1H, d).

Compound 911

15 ^1H N.M.R (CDCl_3) δ (ppm) 0.8 (t), 1.15 (d), 1.4 (quintet), 2.0 (s), 2.3 (s), 3.65 (dd), 7.7 (m), 7.95 (m).

Compound 912

m/z (EI) 357 (M^+).

20

Compound 913

m/z (EI) 320 (M^+).

Compound 914

25 m/z (EI) 330 (M^+).

Compound 915

m/z (EI) 342 (M^+).

30 Compound 916

m/z (EI) 315 (M^+).

Compound 917

m/z (EI) 364 (M^+).

Compound 918

5 *m/z* (EI) 364 (M^+).

Compound 919

m/z (EI) 344 (M^+).

10 Compound 920

^1H N.M.R (CDCl_3) δ (ppm) 2.35 (s), 2.5 (s), 7.4 (d), 7.8 (m), 7.9 (d).

Compound 921

15 ^1H N.M.R (CDCl_3) δ (ppm) 3.9 (3H, m), 6.9-7.05 (2H, m), 7.5-7.75 (2H, m), 7.95 (1H, d),
8.0 (1H, d), 8.5 (1H), 9.1 (1H).

Compound 922

m/z (EI) 328 (M^+).

20 Compound 924

m/z (EI) 382 (M^+).

Compound 925

25 ^1H N.M.R (CDCl_3) δ (ppm) 1.3 (m), 2.7 (m), 4.2 (m), 7.75 (d), 7.95 (d).

Compound 927

m/z (EI) 314 (M^+).

Compound 928

30 *m/z* (EI) 345 (M^+).

Compound 930

^1H N.M.R (CDCl_3) δ (ppm) 2.35 (d), 7.25 (m), 7.5 (d), 7.9 (d), 8.5 (d), 8.65 (s).

Compound 931

m/z (EI) 301 (M^+).

5 Compound 942

^1H N.M.R (CDCl_3) δ (ppm) 2.6 (3H, s), 3.05 (3H, s), 8.0 (5H, m), 8.5 (1H, s).

Compound 943

^1H N.M.R (CDCl_3) δ (ppm) 7.4-7.6 (7H, m), 7.8-8.0 (6H, m), 8.5 (1H, d).

10

Compound 944

m/z (EI) 393 (M^+).

Compound 945

15 ^1H N.M.R (CDCl_3) δ (ppm) 2.7 (3H, s), 7.15 (1H, dd), 7.5-7.65 (3H, m), 7.95 (1H, d), 8.1-8.25 (2H, m), 8.5 (1H, d).

Compound 946

m/z (EI) 396 (M^+).

20

Compound 947

m/z (EI) 368 (M^+).

Compound 948

25 m/z (EI) 376 (M^+).

Compound 949

^1H N.M.R (CDCl_3) δ (ppm) 0.1-1.5 (5H, m), 1.7-1.9 (5H, m), 2.6 (1H, t), 8.0 (1H, m), 8.55 (1H, m).

30

Compound 950

m/z (EI) 406 (M^+).

Compound 951

m/z (EI) 332 (M^+).

Compound 952

5 *m/z* (EI) 349 (M^+).

Compound 953

^1H N.M.R (CDCl_3) δ (ppm) 1.4 (3H, t), 3.0 (2H, q), 7.2 (3H, t) isomer, 7.3 (1H, d), 7.55 (1H, dd), 8.0 (1H, d, m), 8.55 (1H, d, m).

10

Compound 954

^1H N.M.R (CDCl_3) δ (ppm) 2.5 (3H, m), 7.2-7.4 (2H, m), 7.5 (1H, d), 7.9 (1H), 8.4 (1H).

Compound 955

15 ^1H N.M.R (CDCl_3) δ (ppm) 2.6 (s), 4.8 (s), 7.25 (t), 7.5 (dd), 7.9 (m), 8.05 (d), 8.15 (d), 8.5 (s), 8.8 (d).

Compound 956

m/z (EI) 374 (M^+).

20

Compound 957

m/z (EI) 314 (M^+).

Compound 958

25 ^1H N.M.R (CDCl_3) δ (ppm) 7.35-7.6 (8H, m), 7.9 (1H), 8.5 (1H).

Example 13

N-(3-Chloro-5-trifluoromethyl-2-pyridyloxy)-1-naphthalenecarboxamide
(Compound 1012)

30 A mixture of 1-naphthoic acid (0.46 g) and carbonyldiimidazole (0.44 g) in tetrahydrofuran (40 ml) was stirred for 16 hours under a nitrogen atmosphere. The product from stage b) (0.57 g) was then added, and the mixture stirred for 5 days. The solution was poured into saturated brine solution and the organic portion extracted with ethyl acetate (x3), dried

(MgSO₄), filtered and evaporated. The residue was purified by silica gel chromatography (ethyl acetate/petrol) and triturated (diisopropyl ether) to give the title product, m.p. 198-9 °C.

5 Preparation of Starting Materials

a) 2-[[3-Chloro-5-(trifluoromethyl)-2-pyridyl]oxy]-1,3-isindolinedione

2,3-Dichloro-5-trifluoromethylpyridine (50.0 g) was added over 5 minutes to a stirred solution of *N*-hydroxyphthalimide (37.5 g) and triethylamine (25.8 g) in acetone (750 ml). The mixture was refluxed for 8 hours and allowed to stand at room temperature for 16 hours. The solution was filtered and the filtrate evaporated to yield a solid which was partitioned between ethyl acetate and sodium bicarbonate solution. The organic fraction was isolated and the aqueous material re-extracted using further portions of ethyl acetate. The combined organic extracts were washed with water, dried, filtered and evaporated to give the crude product. The residue was triturated with diisopropyl ether to furnish the title compound as a white solid.

b) *O*-[3-Chloro-5-(trifluoromethyl)-2-pyridyl]hydroxylamine

Hydrazine monohydrate (1.7 g) was added to a solution of the product from stage a) (11.3 g) in tetrahydrofuran (200 ml) and the mixture stirred for 16 hours. The mixture was then filtered and the residual solid washed with a small volume of tetrahydrofuran and ethyl acetate, then four times with a 0.02M solution of sodium hydroxide saturated with sodium chloride. The combined aqueous layers were extracted with dichloromethane (x2) and the combined organic extracts dried, filtered and evaporated to give the title compound.


25 Example 14

N-(3-Chloro-5-trifluoromethyl-2-pyridyloxy)-*N*-methyl-1-naphthalenecarboxamide (Compound 1017)

Iodomethane (0.82 g) was added to a stirred solution of the product from Example 13 (Compound 1012) (1.93 g) and potassium *tert*-butoxide (0.61 g) in tetrahydrofuran (50 ml). The reaction mixture was stirred for 48 hours. The solvent was evaporated and the residue partitioned between ethyl acetate and saturated aqueous ammonium chloride. The aqueous layer was separated and extracted with 3 portions of ethyl acetate. The combined organic


phases were dried, filtered and evaporated to give a residue which was purified by silica gel chromatography (ethyl acetate/petrol) to give the title compound, m/z (EI) 380 (M^+).

The following compounds of formula Ir (see Table J), i.e. compounds of general formula I
 5 where A^1 is 3-Cl-5-CF₃-2-pyridyl and L is $-O-N(R^3)C(=O)-$, may be prepared by methods analogous to those of Examples 13 and 14.



(Ir)

Table J

Cmp	R ³	A ²	m.p.(°C)
1001	H	5-Me-2-pyrazinyl	202-6
1002	H	4-tolyl	190-3
1003	H	2-Cl-4-CF ₃ -pyrimidin-5-yl	204-5
1004	H	4-Cl-phenyl	191-3
1005	H	2-NO ₂ -5-(2-Cl-4-CF ₃ -phenoxy)-phenyl	168-70
1006	H	3,5-diMe-4-isoxazolyl	108-11
1007	H	2,4-diMe-5-thiazolyl	152-5
1008	H	4,6-diMeO-2-(α,α -diMe-4-Cl-benzyl)-pyrimidin-5-yl	124-5
1009	H	5-(3,5-diCl-phenoxy)-2-furyl	120-2
1010	H	6-MeO-3-pyridyl	157-9
1011	H	2-naphthyl	180
1012	H	1-naphthyl	198-9
1013	H	2-Cl-phenyl	170
1014	H	3-quinolinyl	238-9
1015	H		oil

Cmp	R ³	A ²	m.p.(°C)
1016	H	4-morpholinyl-3-NO ₂ -phenyl	217-8
1017	Me	1-naphthyl	oil
1018	H	1-naphthyl	218-20
1019	H	2,6-diCl-phenyl	246-7

The mass spectral data of the compounds in Table J which were not solid at room temperature are presented below.

5 Compound 1015
m/z (EI) 412 (M⁺).

Compound 1017
m/z (EI) 380 (M⁺).

10


Example 15
2-Methyl-1,2,3,4-tetrahydro-1-naphthalenone O-1-[3-chloror-5-(trifluoromethyl)-2-pyridyl]oxime
(Compound 1101)

15 The starting material (0.58 g) was dissolved in tetrahydrofuran (5 ml) and to this was added potassium *tert*-butoxide (0.42 g) dissolved in tetrahydrofuran (5 ml). The mixture was stirred overnight and a solution of 2,3-dichloro-5-trifluoromethyl pyridine (0.72 g) in tetrahydrofuran (2 ml) was added. The mixture was stirred for 48 hours at room temperature, then the solvent was evaporated. The residue was partitioned between ethyl acetate and
 20 water. The organic layer was isolated, dried, filtered and evaporated to yield the title product as a light yellow gum, *m/z* (EI) 354 (M⁺).

a) 2-Methyl-1,2,3,4-tetrahydro-1-naphthalenone oxime
 To a solution of 2-methyl-1-tetralone (3.20 g) in methanol (5 ml) was added
 25 hydroxylamine hydrochloride (1.81 g) in methanol (15 ml) and triethylamine (2.63 g). The mixture was stirred at 65°C for 5 hours, allowed to cool and stand at room temperature for 16 hours. The solvent was evaporated and water added to the residue. The product was extracted with ethyl acetate (3 portions) and the combined extracts were dried, filtered and evaporated to give an orange oil. On standing this







separated into two layers. The top layer was removed and the bottom layer slowly solidified to give the title product as an orange solid.





The following compounds of formula Iq (see Table K), i.e. compounds of general formula I
5 where A¹ is 3-Cl-5-CF₃-2-pyridyl and L is -O-N=C(R¹)-, wherein R¹ and A², together with the interconnecting atoms forms a 5- or 6- membered ring, may be prepared by methods analogous to those of Example 15.



(Iq)

Table K

Cmp	RZ	m.p.(°C)
1101	 <chem>CN=C1CCc2ccccc2C1</chem>	oil
1102	 <chem>CN=C1CCc2cc(OC)ccc2C1</chem>	oil
1103	 <chem>CN=C1CCc2cc([N+](=O)[O-])ccc2C1</chem>	oil
1104	 <chem>CN=C1CCOc2ccccc2C1</chem>	oil
1105	 <chem>CN=C1CCc2cc(Cl)ccc2C1</chem>	oil
1106	 <chem>CN=C1CCSc2ccccc2C1</chem>	oil

Cmp	RZ	m.p.(°C)
1107		oil
1108		oil
1109		oil
1110		oil

Those compounds in Table K which do not have discrete melting points have the following characteristic mass spectral data.

5 Compound 1101
m/z (EI) 354 (M^+).

Compound 1102
m/z (EI) 370 (M^+).

10

Compound 1103
m/z (EI) 385 (M^+).

Compound 1104

m/z (EI) 342 (M^+).

Compound 1105

5 *m/z* (EI) 376 (M^+).

Compound 1106

m/z (EI) 358 (M^+).

10 Compound 1107

m/z (EI) 346 (M^+).

Compound 1108

m/z (EI) 370 (M^+).

15

Compound 1109

m/z (EI) 355 (M^+).

Compound 1110

20 *m/z* (EI) 389 (M^+).

Example 16

2-{{[2-(3-Bromo-4-methoxyphenyl)-1*H*-1-imidazolyl]methyl}-3-chloro-5-(trifluoromethyl)pyridine

25 (Compound 1201)

To a solution of 2-(3-bromo-4-methoxyphenyl)-1*H*-imidazole (0.5 g) in tetrahydrofuran was added sodium hydride (0.08 g). After 30 minutes 3-chloro-2-(chloromethyl)-5-trifluoromethyl pyridine (0.46 g) was added and the solution heated until the reaction was complete. The reaction mixture was cooled, poured onto water and the organic phase
30 extracted using dichloromethane, dried and evaporated to yield the crude product as an orange gum. Silica gel column chromatography yielded a gum which was further treated with diisopropyl ether and filtered. Evaporation of the filtrate afforded the title compound, *m/z* (APCI) 445 (M^+).

2-(3-Bromo-4-methoxyphenyl)imidazole was synthesised from 3-bromo-4-methoxybenzonitrile using a method known to the skilled chemist.

Test Example

- 5 Compounds were assessed for activity against one or more of the following:

Phytophthora infestans: late tomato blight

Plasmopara viticola: vine downy mildew

Erysiphe graminis f. sp. tritici: wheat powdery mildew

Pyricularia oryzae: rice blast

- 10 *Leptosphaeria nodorum*: glume blotch

Aqueous solutions or dispersions of the compounds at the desired concentration, including a wetting agent, were applied by spray or by drenching the stem base of the test plants, as appropriate. After a given time, plants or plant parts were inoculated with appropriate test pathogens before or after application of the compounds as appropriate, and kept under
15 controlled environmental conditions suitable for maintaining plant growth and development of the disease. After an appropriate time, the degree of infection of the affected part of the plant was visually estimated. Compounds are assessed on a score of 1 to 3 where 1 is little or no control, 2 is moderate control and 3 is good to total control. At a concentration of 500 ppm (w/v) or less, the following compounds scored 2 or more against the fungi specified.

- 20 *Phytophthora infestans*: 49, 102, 119, 126, 202, 214, 215, 601, 902, 912, 927, 953, 1101 and 1102.

Plasmopara viticola: 5-7, 9, 10, 12, 102, 109, 126, 214, 215, 601, 901, 907, 914, 915, 921, 926-30, 958, 1001 and 1013.

- 25 *Erysiphe graminis f. sp. tritici*: 501, 901, 906, 913-5, 923, 926-931, 933, 935, 936, 948-50, 952, 954, 1008, 1102, 1104, 1107 and 1108.

- 30 *Pyricularia oryzae*: 7, 9, 11, 17, 126, 901, 906, 907, 913, 922, 923, 926-31, 937, 938, 939 and 1001.

Leptosphaeria nodorum: 23, 51, 53, 126, 207, 208, 906, 923, 926, 929, 933, 1007 and 1109.

Claims

- 5 1. The use of a compound of general formula I or salts thereof as phytopathogenic fungicides



(I)

where

10 A^1 is 3-Cl-5-CF₃-2-pyridyl;

A^2 is optionally substituted heterocyclyl or optionally substituted carbocyclyl; excepted when L is -N(R₃)N(R₄)C(=O)- or -CH₂OCH₂-, then A₂ can not contain any heterocyclyl containing N or O;

L is a 3-atom linker selected from the list: -CH(R¹)N(R³)CH(R²)-,

15 -N(R³)N(R⁴)C(=X)-, -C(=X)N(R³)CH(R¹)-, -CH(R¹)OC(=X)-, -CH(R¹)OCH(R²)-, -N(R³)C(=X)N(R⁴)-, -C(R¹)=C(R²)C(=X)-, -CH(R¹)N=C(R²)-, -O-N=C(R¹)-, -O-N(R³)C(=X)-, -N(R³)N(R⁴)CH(R¹), -N(R³)C(Y)=N-, -N=C(Y)-N(R³)-, -C(=X)-N(R³)N(R⁴)-, -C(Y)=N-N(R⁴)- and -N(R³)CH(R¹)C(=X)-; wherein A¹ is attached to the left hand side of
20 linker L;

where R¹ and R², which may be the same or different, are R^b, cyano, nitro, halogen, -OR^b, -SR^b or optionally substituted amino;

R³ and R⁴, which may be the same or different, are R^b, cyano or nitro;

or any R¹, R², R³ or R⁴ group, together with the interconnecting atoms, can form a

25 5- or 6-membered ring with any other R¹, R², R³ or R⁴, or any R¹, R², R³ or R⁴ group, together with the interconnecting atoms can form a 5- or 6-membered ring with A²;

X is oxygen, sulfur, N-OR^b, N-R^b or N-N(R^b)₂; and

Y is halogen, -OR^b, -SR^b, -N(R^b)₂, -NR^b(OR^b) or -NR^bN(R^b)₂;

wherein R^b is alkyl, alkenyl, alkynyl, carbocyclyl or heterocyclyl, each of which may be substituted; or hydrogen or acyl, or two adjacent R^b groups together with the nitrogen atom to which they are attached may form a 5- or 6-membered ring.

5

2. A pesticidal composition comprising at least one compound as claimed in claim 1 in admixture with an agriculturally acceptable diluent or carrier.

3. A method of combating plant pests at a locus infested or liable to be infested therewith, which comprises applying to the locus a compound as claimed in claim 1.

10

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/12604 A1

(51) International Patent Classification⁷: C07D 213/61,
213/89, 405/12, 213/77, 401/12, 213/81, 213/64, 409/12,
417/12, 498/04, 401/06, A01N 43/40

(GB). PATEL, Gita [GB/GB]; Chesterfield House, Wulf-
stan Way, Cambridge CB1 8QL (GB). SCHNATTERER,
Siefan [DE/DE], Schillerring 10, D-65795 Hattersheim
(DE).

(21) International Application Number: PCT/EP00/08268

(22) International Filing Date: 11 August 2000 (11.08.2000)

(74) Agent: MERIGEALT, Shona, Aventus CropScience
S.A., B.P. 9163, F-69263 Lyon Cedex 09 (FR).

(25) Filing Language: English

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(26) Publication Language: English

(30) Priority Data:
9919558.8 18 August 1999 (18.08.1999) GB

(71) Applicant (*for all designated States except US*): AVEN-
TIS CROPSOURCE GMBH [DE/DE]; Brünningstrasse
50, D-65929 Frankfurt am Main (DE).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (*for US only*): COOKE, Tracey
[GB/GB]; 7 Larch Avenue, Brickett Wood, St Albans
AL2 3SN (GB). HARDY, David [GB/GB]; 46 St. Bedes
Gardens, Cambridge CB1 3UF (GB). MOLONEY, Brian,
Anthony [GB/GB]; 2 Crookdale Beck, Oxon OX11
7US (GB). O'MAHONY, Mary, Josephine [GB/GB];
8 Manger's Lane, Duxford, Cambridge CB2 4RN (GB).
PETTETT, Michael, George [GB/GB]; Aventis Crop-
Science UK Ltd., Fyfield Road, Ongar Essx CM5 OHW

Published:


— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 01/12604 A1

(54) Title: FUNGICIDES



(I)

(57) Abstract: Use of compounds of general formula (I) or salts thereof as
phytopathogenic fungicides wherein the various radicals and substituents
are as defined in the description, pesticidal compositions containing them and
method for combatting pests which comprises applying these.

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION			OFGS FILE NO. P/3610-26																																														
<p>As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p>FUNGICIDES</p>																																																	
<p>the specification of which is attached hereto, unless the following box is checked:</p> <p><input checked="" type="checkbox"/> was filed on <u>11 August 2000</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP00/08268</u> and was amended on <u>7 November 2001</u> (if any).</p> <p>I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.</p> <p>I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:</p> <p>Prior Foreign or Provisional Application(s)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">COUNTRY</th> <th style="width: 25%;">APPLICATION NUMBER</th> <th style="width: 25%;">DATE OF FILING (day, month, year)</th> <th style="width: 25%;">PRIORITY CLAIMED UNDER 35 U.S.C. 119</th> </tr> </thead> <tbody> <tr> <td>Great Britain</td> <td>9919558.8</td> <td>18 August 1999</td> <td>YES <u>X</u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> </tbody> </table> <p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 33%;">UNITED STATES APPLICATION NUMBER</th> <th style="width: 33%;">DATE OF FILING (day, month, year)</th> <th style="width: 34%;">STATUS (patented, pending, abandoned)</th> </tr> </thead> <tbody> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> </tbody> </table> <p>I hereby appoint customer no. 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP, and the members of the firm, Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Faber - Reg. No. 24,322; Max Moskowitz - Reg. No. 30,576; James A. Finner - Reg. No. 30,173; William O. Gray, III - Reg. No. 30,943; Louis C. Dujmich - Reg. No. 30,625; and Douglas A. Miro - Reg. No. 31,643, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence.</p> <p>SEND CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP DIRECT TELEPHONE CALLS TO: (212) 382-0700 1180 AVENUE OF THE AMERICAS NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE</td> <td style="width: 33%;">INVENTOR'S SIGNATURE <i>T. Cooke</i></td> <td style="width: 34%;">DATE 25/1/02</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain</td> <td>COUNTRY OF CITIZENSHIP Great Britain</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain</td> </tr> <tr> <td>FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY</td> <td>INVENTOR'S SIGNATURE</td> <td>DATE</td> </tr> <tr> <td colspan="2">RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain</td> <td>COUNTRY OF CITIZENSHIP Great Britain</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain</td> </tr> </table>				COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119	Great Britain	9919558.8	18 August 1999	YES <u>X</u> NO <u> </u>				YES <u> </u> NO <u> </u>				YES <u> </u> NO <u> </u>	UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)										FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE	INVENTOR'S SIGNATURE <i>T. Cooke</i>	DATE 25/1/02	RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain		COUNTRY OF CITIZENSHIP Great Britain	POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain			FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY	INVENTOR'S SIGNATURE	DATE	RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain		COUNTRY OF CITIZENSHIP Great Britain	POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain		
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119																																														
Great Britain	9919558.8	18 August 1999	YES <u>X</u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)																																															
FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE	INVENTOR'S SIGNATURE <i>T. Cooke</i>	DATE 25/1/02																																															
RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain		COUNTRY OF CITIZENSHIP Great Britain																																															
POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain																																																	
FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY	INVENTOR'S SIGNATURE	DATE																																															
RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain		COUNTRY OF CITIZENSHIP Great Britain																																															
POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain																																																	

☒ CONTINUED ON PAGE 2

SH

USC MO US

15/01/02

21:45

Pg: 4

4

UNITED STATES OF AMERICA COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION			OFGS FILE NO. P/3610-26																																														
<p>As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that I verily believe that I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named) of the subject matter which is claimed and for which a patent is sought on the invention entitled:</p> <p>FUNGICIDES</p>																																																	
<p>the specification of which is attached hereto, unless the following box is checked:</p> <p><input checked="" type="checkbox"/> was filed on <u>11 August 2000</u> as United States patent Application Number or PCT International patent application number <u>PCT/EP00/08268</u> and was amended on <u>7 November 2001</u> (if any).</p> <p>I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.</p> <p>I acknowledge the duty to disclose all information known to be material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56.</p> <p>I hereby claim priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate or United States provisional application(s) listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:</p> <p>Prior Foreign or Provisional Application(s)</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 25%;">COUNTRY</th> <th style="width: 25%;">APPLICATION NUMBER</th> <th style="width: 25%;">DATE OF FILING (day, month, year)</th> <th style="width: 25%;">PRIORITY CLAIMED UNDER 35 U.S.C. 119</th> </tr> </thead> <tbody> <tr> <td>Great Britain</td> <td>9919558.8</td> <td>18 August 1999</td> <td>YES <u>X</u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> <tr> <td> </td> <td> </td> <td> </td> <td>YES <u> </u> NO <u> </u></td> </tr> </tbody> </table> <p>I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;">UNITED STATES APPLICATION NUMBER</th> <th style="width: 30%;">DATE OF FILING (day, month, year)</th> <th style="width: 40%;">STATUS (patented, pending, abandoned)</th> </tr> </thead> <tbody> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> <tr><td> </td><td> </td><td> </td></tr> </tbody> </table> <p>I hereby appoint customer no. 2352 OSTROLENK, FABER, GERB & SOFFEN, LLP and the members of the firm, Samuel H. Weiner - Reg. No. 18,510; Jerome M. Berliner - Reg. No. 18,653; Robert C. Faber - Reg. No. 24,322; Max Moskowitz - Reg. No. 30,576; James A. Finder - Reg. No. 30,173; William O. Gray, III - Reg. No. 30,944; Louis C. Dujmich - Reg. No. 30,625; and Douglas A. Miro - Reg. No. 31,643, as attorneys with full power of substitution and revocation to prosecute this application, to transact all business in the Patent & Trademark Office connected therewith and to receive all correspondence.</p> <p>SEND CORRESPONDENCE TO: OSTROLENK, FABER, GERB & SOFFEN, LLP DIRECT TELEPHONE CALLS TO: 1180 AVENUE OF THE AMERICAS (212) 382-0700 NEW YORK, NEW YORK 10036-8403 CUSTOMER NO. 2352</p> <p>I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE</td> <td style="width: 30%;">INVENTOR'S SIGNATURE</td> <td style="width: 40%;">DATE</td> </tr> <tr> <td>RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain</td> <td colspan="2">COUNTRY OF CITIZENSHIP Great Britain</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain</td> </tr> <tr> <td>FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY</td> <td>INVENTOR'S SIGNATURE <i>David Hardy</i></td> <td>DATE 28.1.02</td> </tr> <tr> <td>RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain</td> <td colspan="2">COUNTRY OF CITIZENSHIP Great Britain</td> </tr> <tr> <td colspan="3">POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain</td> </tr> </table>				COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119	Great Britain	9919558.8	18 August 1999	YES <u>X</u> NO <u> </u>				YES <u> </u> NO <u> </u>				YES <u> </u> NO <u> </u>	UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)										FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE	INVENTOR'S SIGNATURE	DATE	RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain	COUNTRY OF CITIZENSHIP Great Britain		POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain			FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY	INVENTOR'S SIGNATURE <i>David Hardy</i>	DATE 28.1.02	RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain	COUNTRY OF CITIZENSHIP Great Britain		POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain		
COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. 119																																														
Great Britain	9919558.8	18 August 1999	YES <u>X</u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
			YES <u> </u> NO <u> </u>																																														
UNITED STATES APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)																																															
FULL NAME OF SOLE OR FIRST INVENTOR Tracey COOKE	INVENTOR'S SIGNATURE	DATE																																															
RESIDENCE (City and either State or Foreign Country) St. Albans AL2 3SN, Great Britain	COUNTRY OF CITIZENSHIP Great Britain																																																
POST OFFICE ADDRESS 7 Larch Avenue, Brickett Wood, St Albans AL2 3SN, Great Britain																																																	
FULL NAME OF SECOND JOINT INVENTOR (IF ANY) David HARDY	INVENTOR'S SIGNATURE <i>David Hardy</i>	DATE 28.1.02																																															
RESIDENCE (City and either State or Foreign Country) Cambridge CB1 3UF, Great Britain	COUNTRY OF CITIZENSHIP Great Britain																																																
POST OFFICE ADDRESS 46 St. Bedes Gardens, Cambridge CB1 3UF, Great Britain																																																	

☒ CONTINUED ON PAGE 2

62

Page 2

Page 3